A new Congressional report includes an article contributed by the Lupus Foundation of America on health disparities among people with lupus and current efforts to improve treatment and diagnosis in minority communities.
Lupus is an autoimmune disease in which people generate antibodies against their own organs. But when antibodies to phospholipid-binding proteins are involved, a variety of complications can occur.
Results from a study of epratuzumab were released today. It did not meet its primary endpoint of clinically reducing the severity of lupus in people with mild to moderate disease. The following is a statement from Sandra C. Raymond, President and CEO